Related Experiment Video
Updated: May 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Cellular cofactors of lentiviral integrase: from target validation to drug discovery
Oliver Taltynov1, Belete A Desimmie, Jonas Demeulemeester
1The Laboratory for Molecular Virology and Gene Therapy, KU Leuven, Leuven, Flanders, Belgium.
Abstract:
To accomplish their life cycle, lentiviruses make use of host proteins, the so-called cellular cofactors. Interactions between host cell and viral proteins during early stages of lentiviral infection provide attractive new antiviral targets. The insertion of lentiviral cDNA in a host cell chromosome is a step of no return in the replication cycle, after which the host cell becomes a permanent carrier of the viral genome and a producer of lentiviral progeny. Integration is carried out by integrase (IN), an enzyme playing also an important role during nuclear import. Plenty of cellular cofactors of HIV-1 IN have been proposed. To date, the lens epithelium-derived growth factor (LEDGF/p75) is the best studied cofactor of HIV-1 IN. Moreover, small molecules that block the LEDGF/p75-IN interaction have recently been developed for the treatment of HIV infection. The nuclear import factor transportin-SR2 (TRN-SR2) has been proposed as another interactor of HIV IN-mediating nuclear import of the virus. Using both proteins as examples, we will describe approaches to be taken to identify and validate novel cofactors as new antiviral targets. Finally, we will highlight recent advances in the design and the development of small-molecule inhibitors binding to the LEDGF/p75-binding pocket in IN (LEDGINs).
Insights
Identifying cellular cofactors essential for lentivirus replication, like lens epithelium-derived growth factor (LEDGF/p75) and transportin-SR2 (TRN-SR2), offers new antiviral targets. Inhibiting protein interactions, such as LEDGF/p75 with integrase (IN), is a promising HIV treatment strategy.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Lentiviruses rely on host cell proteins (cofactors) for their life cycle.
- Host-viral protein interactions during early infection are key antiviral targets.
- HIV-1 integrase (IN) mediates viral DNA integration and nuclear import.
Purpose of the Study:
- To explore cellular cofactors as novel antiviral targets.
- To validate methods for identifying and validating new cofactors.
- To highlight advancements in small-molecule inhibitors targeting HIV-1 IN.
Main Methods:
- Focus on lens epithelium-derived growth factor (LEDGF/p75) and transportin-SR2 (TRN-SR2) as model cofactors.
- Review strategies for cofactor identification and validation.
- Discuss the development of small-molecule inhibitors (LEDGINs).
Main Results:
- LEDGF/p75 is a well-characterized cofactor of HIV-1 IN.
- TRN-SR2 is implicated in HIV-1 nuclear import.
- Small molecules blocking LEDGF/p75-IN interaction are in development for HIV treatment.
Conclusions:
- Targeting cofactor-IN interactions presents a viable strategy for antiviral drug development.
- LEDGINs show promise as therapeutic agents against HIV infection.
- Further research into novel cofactors can yield new targets for combating lentiviral infections.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview

